A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1274 participants.
Also called NCT02398656
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,274 participants
- Sponsor
- Registry
-
NCT02398656
-
- Main results
- Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial
- Other papers using this trial's data
- Outcomes After Minor Ischemic Stroke in Older Patients Treated With IV Thrombolysis vs Standard of Care in the TEMPO-2 Trial
- Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial
- Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Austria, Brazil, Canada, Finland, Ireland, New Zealand, Singapore, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02398656. Randomized; single masking; primary purpose treatment. Start 2015-04-01 (actual); primary completion 2024-01-19 (actual). Results posted on 2025-01-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
- Acronym
- TEMPO-2
- Condition
- Stroke, Acute
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Antiplatelet treatment
- Lead sponsor
- University of Calgary
Record details
- Record id
cardio:ct-nct02398656- Content hash
dc85fd4e47516b6b1fac1c8cff412f71b829dd703cf8044bbc0af232d582a436